Fusidic acid in dermatology: An updated review

European Journal of Dermatology

Volumn 20, Issue 1, 2010, Pages 6-15

  Schöfer, Helmut ^a   Simonsen, Lene ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Medical Affairs   (Denmark)

Author keywords

Fusidic acid; Impetigo; Infected eczema; Sodium fusidate; Staphylococcus aureus

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BENZOIC ACID PLUS SALICYLIC ACID; BETAMETHASONE; BETAMETHASONE PLUS CLIOQUINOL; BETAMETHASONE PLUS FUSIDIC ACID; BETAMETHASONE PLUS NEOMYCIN; BETAMETHASONE VALERATE PLUS GENTAMYCIN; CIPROFLOXACIN; CLIOQUINOL; DAKTACORT; DICLOXACILLIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUCIBET; FUCIBET LIPID; FUCICORT; FUCICORT LIPID; FUCIDIN H; FUSIDIC ACID; FUSIDIC ACID PLUS HYDROCORTISONE; HYDROGEN PEROXIDE; NEBACETIN; NEOMYCIN; PENICILLIN G; POLYTRIM; POVIDONE IODINE; PRISTINAMYCIN; PSEUDOMONIC ACID; RETAPAMULIN; UNCLASSIFIED DRUG;

ABSCESS; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE REACTION; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; CONTACT DERMATITIS; DERMATOLOGY; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ECZEMA; ERYTHRASMA; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HUMAN; IMPETIGO; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PARONYCHIA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROPIONIBACTERIUM ACNES; PSORIASIS; PYODERMA; RECOMMENDED DRUG DOSE; REVIEW; SKIN ABSCESS; SKIN DISEASE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; WOUND INFECTION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; FUSIDIC ACID; GLUCOCORTICOIDS; HUMANS; SKIN DISEASES, INFECTIOUS;

EID: 76749153773     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0833     Document Type: Review

References (112)

1. Burns K, Cannon M, Cundliffe E. A resolution of conflicting reports concerning the mode of action of fusidic acid. FEBS Lett 1974; 40: 219-23.
2. Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol 1998; 139 (Suppl. 53): 3740.
3. Vickers CFH. Percutaneous absorption of sodium fusidate and fusidic acid. Br J Dermatol 1969; 81: 902-8.
4. Stüttgen G, Bauer E. Penetration and permeation into human skin of fusidic acid in different galenical formulation. Arzneim Forsch 1988; 38: 730-5.
5. Taburet AM, Guibert J, Kitzis MD, Sorensen H, Acar JF, Singlas E. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. J Antimicrob Chemother 1990; 25 (Suppl. B): 23-31.
6. Simonsen L, Fullerton A. Development of an in vitro skin permeation model simulating atopic dermatitis skin for the evaluation of dermatological products. Skin Pharmacol Physiol 2007; 20: 230-6.
7. Vaillant L, Machet L, Taburet AM, Sorensen H, Lorette G. Levels of fusidic acid in skin blister fluid and serum after repeated administration of two dosages (250 and 500 mg). Br J Dermatol 1992; 126: 591-5.
8. Sørensen B, Sejrsen P, Thomsen M. Fucidin, pro-staphlin, and penicillin concentration in burn crusts. Acta Chir Scand 1966; 131: 423-9.
9. Vaillant L, Le Guellec C, Jehl F, Barruet R, Sorensen H, Roiron R, et al. Comparative diffusion of fusidic acid, oxacillin, and pristinamycin in interstitial dermal fluid after repeated oral administration. Ann Dermatol Venereol 2000; 127: 33-9.
10. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210-9.
11. Soriano F, Zapardiel J, Nieto E. Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents. Antimicrob Agents Chemother 1995; 39: 208-14.
12. Hassan H, O'Hare MD, Felmingham D. In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria. Singapore Med J 1990; 31: 56-8.
13. Leclercq R, Bismuth R, Casin I, Cavallo JD, Croizé J, Felten A. In vitro activity of fusidic acid against streptococci isolated from skin and soft tissue infections. J Antimicrob Chemother 2000; 45: 27-9.
14. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999; 12 (Suppl. 2): S59-66.
15. Nordin P, Mobacken H. A comparison of fusidic acid and flucloxacillin in the treatment of skin and soft-tissue infection. Eur J Clin Res 1994; 5: 97-106.
16. Machet L, Puissant A, Vaillant L. Essai comaratif multicentrique de l'acide fusidique comprimés à deux posologies (500 mg et 1 g/jour) versus prestinamycine comprimés (2 g/jour) dans le traitement des infections cutanées. Nouv Dermatol 1994; 13: 520-4 [Treatment of skin infections with two dosages of fusidic acid (500 mg/day and 1 g/day) compared with pristinamycin 2 g/day: a multicenter randomised study.].
17. Carr WD, Wall AR, Georgala-Zervogiani S, Stratigos J, Gouriotou K. Fusidic acid tablets in patients with skin and soft tissue infections: A dose finding study. Eur J Clin Res 1994; 5: 87-95.
18. Newby MR. Comparative efficacy of fusidic acid and ciprofloxacin in skin and soft tissue infection. J Clin Res 1999; 2: 77-84.
19. Morris CDE, Talbot DT. A comparison of fusidic acid and flucloxacillin capsules in the treatment of skin and soft-tissue infection. J Clin Res 2000; 3: 1-14.
20. Wall ARJ, Menday AP. Fusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study. J Clin Res 2000; 3: 12-28.
21. Claudy A. Groupe Francais d'Etude. Pyodermites superficielles nécessitant une antibiothérapie orale - Acide fusidique versus pristinamycine. Presse Med 2001; 30: 364-8 [Superficial pyoderma requiring oral antibiotic therapy - fusidic acid versus pristinamycin.].
22. LEO Pharma 2008. Summary of Product characteristics - Fucidin film coated tablets.
23. LEO Pharma 2008: Summary of Product characteristics - Fucidin suspension.
24. Christiansen K. Fusidic acid adverse drug reactions. Int J Antimicrob Agents 1999; 12 (Suppl. 2): S3-9.
25. Török E, Somogyi T, Rutkai K, Iglesias L, Bielsa I. Fusidic acid suspension twice daily: a new treatment schedule for skin and soft tissue infection in children with improved tolerability. J Dermatolog Treat 2004; 15: 158-63.
26. Pakrooh H. Comparative trial of Fucidin ointment and Fucidin cream in skin sepsis. J Int Med Res 1980; 8: 425-9.
27. Baldwin RJ, Cranfield R. A multi-centre general practice trial comparing Fucidin ointment and Fucidin cream. Br J Clin Pract 1981; 35: 157-60.
28. Macotela Ruiz E, Duran Bermudez H, Kuri Con FJ, Arevalo Lopez A, Villalobos Ibarra JL. Evaluación de la eficacia y toxicidad del ácido fusidico local frente a dicloxacilina oral en infecciones de la piel. Med Cutanea Ibero Lat Am 1988; 16: 171-3 [Evaluation of the efficacy and toxicity of local fusidic acid compared with oral dicloxacillin in skin infections.].
29. Langdon CG, Mahapatra KS. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in acute skin sepsis. Curr Ther Res 1990; 48: 174-9.
30. El Mofty M, Harvey S, Gibson J, Calthrop JG, Marks P. Trimethoprim-polymixin B sulphate cream compared with fusidic acid cream in the treatment of superficial bacterial infection of the skin. J Int Med Res 1990; 18: 89-93.
31. Jaafar R, Pettit J, Lumpur K, Gibson JR, Harvey SG, Marks P. Trimethoprim-polymixin B sulphate cream versus fusidic acid cream in the treatment of pyodermas; an update. Int J Dermatol 1991; 130: 746.
32. Hamann K, Thorn P. Systemic or local treatment of erythrasma? A comparison between erythromycin tablets and Fucidin cream in general practice. Scand J Prim Health Care 1991; 9: 35-9.
33. Sutton JB. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in facial impetigo. Curr Ther Res 1992; 51: 673-8.
34. Christensen OB, Anehus S. Hydrogen peroxide cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. Acta Derm Venereol 1994; 74: 460-2.
35. Koning S, van Suijlekom-Smit L, Nouwen J, Verduin CM, Bernsen RM, Oranje AP, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2002; 324: 203-7.
36. Jackson N, VerlingW. Deasy Df, MacMahon JJ, Sherry TB. Treatment of cutaneous infections with Fucidin ointment. Clin Trials J 1966; 3: 591-5.
37. Somerville DA, Noble WC, White PM, Seville RH, Savin JA. Sodium fusidate in the treatment of erythrasma. Br J Dermatol 1971; 85: 450-3.
38. Pakrooh H. A comparison of sodium fusidate ointment (Fucidin) alone versus oral antibiotic therapy in soft-tissue infections. Curr Med Res Opin 1977; 5: 289-94.
39. Cassels-Brown G. A comparative study of Fucidin ointment and Cicatrin cream in the treatment of impetigo. Br J Clin Pract 1981; 35: 153-5.
40. Zelvelder WG. A double-blind comparative study of sodium fusidate (topical), amoxycillin (oral) and the combination of both drugs in skin infections. Tijdschr Geneesmiddelenonderz 1984; 9: 87-92.
41. Morley PAR, Munot LD. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin 1988; 11: 142-8.
42. White DG, Collins PO, Rowsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice - a comparison of mupirocin with sodium fusidate. J Infect 1989; 18: 221-9.
43. Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol 1989; 20: 1083-7.
44. Jasuja K, Gupta SK, Arora DR, Gupta V. Bacteriology of primary pyodermas and comparative efficacy of topical application of mupirocin and sodium fusidate ointments in their treatment. Indian J Dermatol Venereol Leprol 2001; 67: 132-4.
45. Oranje AP, Chosidow O, Sacchidanand S, et al. TOC100224 Study Team. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007; 215: 331-40.
46. Koning S, Verhagen AP, van Suijlekom-Smit L, Morris A, Butler CC, van der Wouden JC, et al. Interventions for impetigo. Cochrane Database of Systematic Reviews 2004: CD003261 (Review).
47. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract 2003; 53: 480-7.
48. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998; 41: 11-8.
49. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003; 51: 613-7.
50. Johnston GA. Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants. Expert Rev Anti-Infect Ther 2004; 2: 439-46.
51. Tschachler E, Brockmeyer N, Effendy I, Geiss HK, Harder S, Hartmann M, et al. Streptococcal infections of the skin and mucous membranes. J Dtsch Dermatol Ges 2007; 5: 527-32.
52. Karup C. Safety review of fusidic acid cream and ointment for the treatment of infected dermatoses. 16th Congress of the European Academy of Dermatology and Venereology, Vienna, Austria, 16-20 May 2007: Poster P110.
53. Morris SD, Rycroft RJ, White IR, Wakelin SH, McFadden JP. Comparative frequency of patch test reactions to topical antibiotics. Br J Dermatol 2002; 146: 1047-51.
54. Jappe U, Schnuch A, Uter W. Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995-1999. Br J Dermatol 2003; 149: 87-93.
55. De Pádua CA, Uter W, Schnuch A. Contact allergy to topical drugs: prevalence in a clinical setting and estimation of frequency at the population level. Pharmacoepidemiol Drug Saf 2007; 16: 377-84.
56. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006; 155: 680-7.
57. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323-8.
58. Thestrup-Pedersen K. Treatment strategies and compliance for the adult patient with infected atopic eczema. Acta Derm Venereol 2005 (Suppl. 215): 36-40.
59. Chu AC. Antibacterial/steroid combination therapy in infected eczema. Acta Dem Venereol 2008 (Suppl 216): 28-34.
60. Ramsay CA, Savoie JM, Gilbert M, Gidon M, Kidson P. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 1): S15-22.
61. Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126-31.
62. Poyner TF, Dass BK. Comparative efficacy and tolerability of fusidic acid/hydrocortisone cream (Fucidin H cream) and miconazole/ hydrocortisone cream (Daktacort cream) in infected eczema. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 1): S23-30.
63. Wilkinson JD, Leigh DA. Comparative efficacy of betamethasone and either fusidic acid or neomycin in infected or potentially infected eczema. Curr Ther Res 1985; 38: 177-82.
64. Javier PR, Ortiz M, Torralba L, Montinola FL, Ke ML, Canete R. Fusidic acid/betamethasone in infected dermatoses - a double- blind comparison with neomycin/betamethasone. Br J Clin Pract 1986; 40: 235-8.
65. Strategos J. Fusidic acid-betamethasone combination in infected eczema: an open, randomized comparison with gentamicinbetamethasone combination. Pharmatherapeutica 1986; 4: 601-6.
66. Hill VA, Wong E, Corbett MF, Menday AP. Comparative efficacy of betamethasone/clioquinol (Betnovate C) cream and betamethasone/ fusidic acid (Fucibet) cream in the treatment of infected hand eczema. J Dermatolog Treat 1998; 9: 15-9.
67. Schultz Larsen F, Simonsen L, Melgaard A, Wendicke K, Henriksen AS. An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol 2007; 87: 62-8.
68. Karup C. Safety review of fusidic acid/steroid combinations for the treatment of infected dermatoses. 16th Congress of the European Academy of Dermatology and Venereology, Vienna, Austria, 16-20 May 2007: Poster P63.
69. Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chemother 1990; 25 (Suppl. B): 1-5.
70. O'Neill AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 647-50.
71. Besier S, Ludwig A, Brade V, Wichelhaus TA. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol 2003; 47: 463-9.
72. O'Neill AJ, Larsen AR, Henriksen AS, Chopra I. A fusidic acidresistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob Agents Chemother 2004; 48: 3594-7.
73. Besier S, Ludwig A, Brade V, Wichelhaus TA. Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 1426-31.
74. Chopra I. Mechanisms of resistance to fusidic acid in Staphylococcus aureus. J Gen Microbiol 1976; 96: 229-38.
75. Evans RJ, Waterworth PM. Naturally-occurring fusidic acid resistance in staphylococci and its linkage to other resistances. J Clin Pathol 1966; 19: 555-60.
76. O'Brien FG, Price C, Grubb WB, Gustafson JE. Genetic characterization of the fusidic acid and cadmium resistance determinants of Staphylococcus aureus plasmid pUB101. J Antimicrob Chemother 2002; 50: 313-21.
77. O'Neill AJ, Chopra I. Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol Microbiol 2006; 59: 664-76.
78. Turnidge JD, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12: S35-44.
79. Livermore D, James D, Duckworth G, Stephens P. Fusidic-acid use and resistance. Lancet 2002; 360: 806.
80. Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 2004; 89: 74-7.
81. Tveten Y, Jenkins A, Kristiansen BE. A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway. J Antimicrob Chemother 2002; 50: 873-6.
82. Osterlund A, Eden T, Olsson-Liljequist B, Haeggman S, Kahlmeter G. Swedish Study. Group on Fusidic Acid-resistant Staphylococcus aureus. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand J Infect Dis 2002; 34: 729-34.
83. Osterlund A, Kahlmeter G, Haeggman S, Olsson-Liljequist B. Swedish Study Group On Fusidic Acid Resistant S Aureus. Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study. Scand J Infect Dis 2006; 38: 334.
84. Lorette G, Beaulieu P, Bismuth R, et al. Infections cutanées communautaires bactéries en cause et sensibilité aux antibiotiques. Ann Dermatol Venereol 2003; 130: 723-8 [Community-acquired cutaneous infections: causal role of some bacteria and sensitivity to antibiotics.].
85. Hoeger PH. Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. Pediatr Allergy Immunol 2004; 15: 474-7.
86. Bernard P, Jarlier V, Santerre-Henriksen A. 2007. Sensibilité aux antibiotiques des souches de S. aureus responsables d'infections cutanées communautaires. Ann Dermatol Venereol 2008; 135: 13-9 [Antibiotic susceptibility of S. aureus strains responsible for cutaneous infections in the community.].
87. Thaçi D, Schöfer H. Topische Antibiotika zur Therapie von Hautinfektionen. Hautarzt 2005; 56: 381-96 [Topical antibiotics for therapy of skin infections].
88. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9: 978-84.
89. Monecke S, Slickers P, Hotzel H, et al. Microarray-based characterisation of a Panton-Valentine leukocidin-positive communityacquired strain of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12: 718-28.
90. Jappe U, Heuck D, Strommenger B, et al. Staphylococcus aureus in dermatology outpatients with special emphasis on communityassociated methicillin-resistant strains. J Invest Dermatol 2008; 128: 2655-64.
91. Turnidge JD, Nimmo GR, Francis G. Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR). Med J Aust 1996; 164: 68-71.
92. Rennie RP. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J Cutan Med Surg 2006; 10: 277-80.
93. Howden BP, Grayson ML. Dumb and dumber - the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006; 42: 394-400.
94. Vasquez JE, Walker ES, Franzus BW, et al. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 2000; 21: 459-64.
95. Menday AP, Nobel WC. Topical betamethasone/fusidic acid in eczema: efficacy against and emergence of resistance in Staphylococcus aureus. J Dermatolog Treat 2000; 11: 143-9.
96. Ravenscroft JC, Layton AM, Eady EA, et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant Staphylococcus aureus in infected atopic eczema. Br J Dermatol 2003; 148: 1010-7.
97. Perera G, Hay R. A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol 2005; 19: 531-45.
98. Belgisch Centrum voor Farmacotherapeutische Informatie. Behandeling van impetigo. [Treatment of impetigo]. Folio Pharmacotherapeutica 2005; 32; Febr: 13-14. Available at: http://www.bcfi.be/ Folia/index.cfm?FoliaWelk= F32N02D&keyword=Behandeling% 20van%20impetigo Accessed 20 August 2007.
99. Rosser WW, Pennie RA. Pilla NJ and the Anti-Infective Review Panel. Anti-infective guidelines for community-acquired infections. Toronto: MUMS Guideline Clearinghouse, 2005.
100. Institute of Rational Pharmacotherapy, Denmark, 2007. Infektionssygdomme. [Skin infections]. Available at http://www.irf.dk/ dk/rekommandationsliste/ baggrundsnotater/infektionssygdomme/ antibiotika-systemisk-brug. htm#Baggrundsnotat Accessed 20 August 2007.
101. French Health Products Safety Agency (AFSSAPS). Prescription des antibiotiques par voie locale dans les infections cutanées bacteriennes primitives et secondaires. [Prescribing of local antibiotics in primary and secondary bacterial cutaneous infections.] July 2004. Available at: http://afssaps.sante.fr/pdf/5/rbp/dermreco.pdf. Accessed 18 October 2007.
102. Schöfer H, Brockmeyer N, Dissemond J, Effendy I, Esser S, Geiss HK, et al. Staphylokokken-Infektionen der Haut und Schleimhäute. Leitlinie der Deutschen Dermatologischen Gesellschaft (DDG), Arbeitsgemeinschaft für Dermatologische Infektiologie (ADI). J Dtsch Dermatol Ges 2005; 3: 726-34 [Staphylococcal infections of the skin and mucous membranes. Guideline of the German Dermatologic Society, Study Group of Dermatologic Infectiology.].
103. Nederlands Huisartsen Genootschap. Bacteriële huidinfecties. [Bacterial skin diseases.] Code M68. August 2007. Available at: http://nhg.artsennet.nl/upload/104/standaarden/M68/start.htm Accessed 27 August 2008.
104. Retapamulin for impetigo and other infections. Drugs and Therapeutics Bulletin 2008; 46: 76-8.
105. Akdis C, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/ PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118: 152-69.
106. De Groot AC. Contact allergy to sodium fusidate. Contact Dermatitis 1982; 8: 429.
107. Baptista A, Barros MA. Contact dermatitis from sodium fusidate. Contact Dermatitis 1990; 23: 186-7.
108. Giordano-Labadie F, Pelletier N, Bazex J. Contact dermatitis from sodium fusidate. Contact Dermatitis 1996; 34: 159.
109. Lee AY, Joo HJ, Oh JG, Kim YG. Allergic contact dermatitis from sodium fusidate with no underlying dermatosis. Contact Dermatitis 2000; 42: 53.
110. De Castro Martinez FJ, Ruiz FJ, Tornero P, De Barrio M, Prieto A. Systemic contact dermatitis due to fusidic acid. Contact Dermatitis 2006; 54: 169.
111. Bobadilla-González P, García-Menaya JM, Cordobés-Durán C, Pérez-Rangel I, Sánchez-Vega S. Generalized urticaria to fusidic acid. Allergy 2009; 64: 817-8.
112. Lannergård. Norström T, Hughes D. Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2059-65.